-$0.27 EPS Expected for AtriCure, Inc. (NASDAQ:ATRC) This Quarter

Equities research analysts expect AtriCure, Inc. (NASDAQ:ATRCGet Rating) to report ($0.27) earnings per share for the current quarter, according to Zacks. Five analysts have made estimates for AtriCure’s earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.36). AtriCure reported earnings per share of ($0.38) during the same quarter last year, which suggests a positive year over year growth rate of 28.9%. The business is scheduled to issue its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that AtriCure will report full year earnings of ($0.93) per share for the current financial year, with EPS estimates ranging from ($1.22) to ($0.64). For the next year, analysts expect that the company will post earnings of ($0.60) per share, with EPS estimates ranging from ($0.87) to ($0.33). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for AtriCure.

AtriCure (NASDAQ:ATRCGet Rating) last released its earnings results on Tuesday, February 15th. The medical device company reported ($0.30) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.04). The firm had revenue of $73.22 million during the quarter, compared to analysts’ expectations of $72.50 million. AtriCure had a net margin of 18.30% and a negative return on equity of 11.96%. During the same quarter in the previous year, the business earned ($0.18) EPS.

A number of research firms recently weighed in on ATRC. Canaccord Genuity Group reduced their price objective on AtriCure from $120.00 to $88.00 and set a “buy” rating for the company in a research report on Wednesday, February 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $79.00 price objective on shares of AtriCure in a research report on Thursday, February 24th. TheStreet lowered AtriCure from a “b-” rating to a “c” rating in a research report on Wednesday, February 16th. Zacks Investment Research lowered AtriCure from a “buy” rating to a “hold” rating in a report on Friday, February 18th. Finally, BTIG Research reissued a “buy” rating and issued a $94.00 target price on shares of AtriCure in a report on Monday, March 14th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, AtriCure has a consensus rating of “Buy” and an average target price of $91.33.

Shares of ATRC traded down $2.07 on Friday, reaching $51.93. The stock had a trading volume of 521,835 shares, compared to its average volume of 198,255. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 48.53 and a beta of 1.10. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.78 and a current ratio of 3.47. The company has a 50-day simple moving average of $62.38 and a 200-day simple moving average of $67.32. AtriCure has a 12-month low of $51.39 and a 12-month high of $89.18.

In other news, insider Tonya Austin sold 1,409 shares of the firm’s stock in a transaction on Friday, March 4th. The stock was sold at an average price of $67.66, for a total value of $95,332.94. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders sold 5,807 shares of company stock worth $394,645. Company insiders own 5.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in AtriCure by 1.7% during the fourth quarter. BlackRock Inc. now owns 3,714,691 shares of the medical device company’s stock valued at $258,284,000 after purchasing an additional 61,430 shares in the last quarter. Alliancebernstein L.P. lifted its position in AtriCure by 18.7% during the fourth quarter. Alliancebernstein L.P. now owns 3,455,856 shares of the medical device company’s stock valued at $240,286,000 after purchasing an additional 544,296 shares in the last quarter. Invesco Ltd. lifted its position in AtriCure by 7.2% during the fourth quarter. Invesco Ltd. now owns 2,437,617 shares of the medical device company’s stock valued at $169,487,000 after purchasing an additional 162,718 shares in the last quarter. Credit Suisse AG lifted its position in AtriCure by 6.4% during the fourth quarter. Credit Suisse AG now owns 1,211,722 shares of the medical device company’s stock valued at $84,251,000 after purchasing an additional 73,376 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its position in AtriCure by 5.6% during the third quarter. Macquarie Group Ltd. now owns 1,093,710 shares of the medical device company’s stock valued at $76,068,000 after purchasing an additional 57,777 shares in the last quarter. Institutional investors own 93.28% of the company’s stock.

AtriCure Company Profile (Get Rating)

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Recommended Stories

Get a free copy of the Zacks research report on AtriCure (ATRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.